Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MDGL |
---|---|---|
09:32 ET | 1998 | 208.21 |
09:36 ET | 300 | 209 |
09:38 ET | 297 | 208.23 |
09:45 ET | 1501 | 208.5 |
09:48 ET | 194 | 208 |
09:50 ET | 300 | 208.86 |
09:52 ET | 300 | 208.8 |
09:54 ET | 1389 | 208.86 |
09:56 ET | 1300 | 208.84 |
09:59 ET | 1730 | 208 |
10:01 ET | 153 | 207.5 |
10:03 ET | 100 | 207.395 |
10:06 ET | 100 | 207.76 |
10:08 ET | 161 | 207.5 |
10:10 ET | 553 | 208.01 |
10:12 ET | 293 | 208.54 |
10:15 ET | 300 | 208.3 |
10:17 ET | 370 | 208.045 |
10:19 ET | 880 | 207.96 |
10:21 ET | 100 | 207.73 |
10:24 ET | 100 | 207.745 |
10:26 ET | 100 | 207.46 |
10:32 ET | 300 | 207.54 |
10:37 ET | 487 | 207 |
10:44 ET | 400 | 206.41 |
10:48 ET | 525 | 206.706 |
10:51 ET | 500 | 206.11 |
10:53 ET | 1452 | 206.3 |
11:00 ET | 455 | 207.21 |
11:02 ET | 390 | 207.7524 |
11:09 ET | 500 | 207.52 |
11:11 ET | 400 | 207.205 |
11:13 ET | 100 | 207.07 |
11:15 ET | 400 | 207.18 |
11:18 ET | 200 | 207.21 |
11:20 ET | 1558 | 207.55 |
11:24 ET | 476 | 206.99 |
11:27 ET | 150 | 206.91 |
11:29 ET | 876 | 206 |
11:31 ET | 100 | 205.8 |
11:33 ET | 444 | 205.62 |
11:42 ET | 315 | 205.31 |
11:44 ET | 1594 | 205.3 |
11:45 ET | 2300 | 205.725 |
11:54 ET | 1697 | 204.865 |
11:56 ET | 1500 | 205 |
11:58 ET | 2669 | 205.015 |
12:00 ET | 1350 | 205.66 |
12:02 ET | 826 | 205.75 |
12:03 ET | 400 | 205.895 |
12:05 ET | 100 | 206 |
12:07 ET | 200 | 205.83 |
12:12 ET | 200 | 205.66 |
12:14 ET | 600 | 205.87 |
12:18 ET | 500 | 206.09 |
12:30 ET | 200 | 206.0488 |
12:32 ET | 600 | 205.62 |
12:34 ET | 200 | 205.72 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Madrigal Pharmaceuticals Inc | 4.5B | -8.1x | --- |
Immunovant Inc | 4.3B | -15.4x | --- |
BridgeBio Pharma Inc | 4.7B | -9.5x | --- |
Biohaven Ltd | 5.1B | -5.7x | --- |
Crinetics Pharmaceuticals Inc | 5.2B | -15.9x | --- |
Krystal Biotech Inc | 5.1B | 47.9x | --- |
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.5B |
---|---|
Revenue (TTM) | $14.6M |
Shares Outstanding | 21.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.45 |
EPS | $-25.50 |
Book Value | $20.39 |
P/E Ratio | -8.1x |
Price/Sales (TTM) | 309.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,622.65% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.